What Exactly Is This New Patent From Progenity?

Progenity, Inc. is a biotechnology company. Progenity promotes its pipeline designed for women’s health, gastrointestinal health, and oral biotherapy. At the moment, its market cap represents more than 252 million dollars, and the trading volume is 23,353,325 shares. The stock market of PROG today demonstrates a significant growth of almost $1.5400 by 20% profit, and in the pre-market, it is open at $1.6300. In this context, it might be the right time for investors to look into the announcement made by the company on Tuesday.


Progenity proclaimed that it has added another significant U.S. Patent No. 11,230,731 issued by USPTO to its portfolio, which is related to the developed platform for analysis for detection of a single molecule. The company noted that the latest patent covers crucial compositions and labeling methods. However, there are different types of patents that support the single-molecule detection platform Progenity, which has consistently identified, one might say, different families of patents. Lastly, the company has more than 200 pending patent applications, while 180 patents have been granted and 96 patent portfolios of its own.